Respiree

News

Health tech Respiree, developer of AI platforms to manage disease progression, has announced the successful closing of an $11.6m Series A financing.

News

The real-time sensor can be used to spot exacerbations of COPD days in advance, says company.

News

Pressure is building on Amgen to withdraw rare disease therapy Tavneos, after the CHMP recommended its marketing authorisation by revoked in the EU.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.